-
Neurocrine Biosciences Exceeds Expectations With Ingrezza Launch
Thursday, November 2, 2017 - 1:48pm | 661The performance of the tardive dyskinesia drug Ingrezza had sell-side analysts gushing over Neurocrine Biosciences, Inc. (NASDAQ: NBIX)'s third-quarter results. Given the buoyancy surrounding Ingrezza, analysts scrambled to designate Neurocrine as their top mid-cap pick. Ingrezza...